Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer by Escudero-Esparza, Astrid et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Complement inhibitor CSMD1 acts as tumor suppressor in 
human breast cancer
Astrid Escudero-Esparza1, Michael Bartoschek2,*, Chrysostomi Gialeli1,*, Marcin Okroj3, 
Sioned Owen4, Karin Jirström5, Akira Orimo6, Wen G. Jiang4, Kristian Pietras2, Anna 
M. Blom1
1Department of Translational Medicine, Lund University, Malmö, Sweden
2Department of Laboratory Medicine, Lund University, Lund, Sweden
3Department of Medical Biotechnology, Medical University of Gdańsk, Gdańsk, Poland
4Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Cardiff, UK
5Department of Clinical Sciences, Lund University, Lund, Sweden
6Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan
*These authors contributed equally to this work
Correspondence to: Anna M. Blom, email: anna.blom@med.lu.se
Keywords: breast cancer, tumor suppressor, CSMD1, complement system, invasion
Received: June 15, 2016    Accepted: October 11, 2016    Published: October 18, 2016
ABSTRACT
Human CUB and Sushi multiple domains 1 (CSMD1) is a membrane-bound 
complement inhibitor suggested to act as a putative tumor suppressor gene, since 
allelic loss of this region encompassing 8p23 including CSMD1 characterizes various 
malignancies. Here, we assessed the role of CSMD1 as a tumor suppressor gene in the 
development of breast cancer in vitro and in vivo. We found that human breast tumor 
tissues expressed CSMD1 at lower levels compared to that in normal mammary tissues. 
The decreased expression of CSMD1 was linked to a shorter overall survival of breast 
cancer patients. We also revealed that expression of CSMD1 in human breast cancer cells 
BT-20 and MDA-MB-231 significantly inhibited their malignant phenotypes, including 
migration, adhesion and invasion. Conversely, stable silencing of CSMD1 expression in 
T47D cells enhanced cancer cell migratory, adherent and clonogenic abilities. Moreover, 
expression of CSMD1 in the highly invasive MDA-MB-231 cells diminished their signaling 
potential as well as their stem cell-like properties as assessed by measurement of 
aldehyde dehydrogenase activity. In a xenograft model, expression of CSMD1 blocked 
the ability of cancer cells to metastasize to secondary sites in vivo, likely via inhibiting 
local invasion but not the extravasation into distant tissues. Taken together, these 
findings demonstrate the role of CSMD1 as a tumor suppressor gene in breast cancer.
INTRODUCTION
Breast cancer is the most frequent cancer in women 
and many pathophysiological mechanisms leading to its 
development remain to be elucidated.  Some of these 
relate to tumor suppressor genes defined as a group of 
genes that when down-regulated, mutated or absent 
contribute actively to carcinogenesis. Inactivation of 
tumor suppressor genes is a fundamental hallmark of 
cancer [1] and their functions span from inhibition of cell 
growth to regulation of the cell cycle [2]. 
Human CUB and Sushi multiple domains 1 
(CSMD1) is a large (~ 390 kDa) membrane-bound 
complement inhibitor [3]. It is composed of 14 N-terminal 
CUB domains separated by single complement control 
protein (CCP) domains and followed by 15 consecutive 
CCP domains. It has a single membrane-spanning domain 
at the C-terminus and a small cytoplasmic tail of 56 
amino acids with a putative tyrosine phosphorylation site. 
Therefore, CSMD1 has been proposed to have an active 
role in cell cycle regulation and controlling apoptosis, for 
example via the Smad pathway in melanoma cells [4]. 
CSMD1 is highly expressed in testis, cerebral cortex, 
cerebellum and brain white matter. A weaker expression 
was seen in breast, placenta and thyroid gland [3]. 
The CSMD1 gene occupies over 2 Mb in the short 
arm of chromosome 8 (8p23) [5]. Allelic loss, mutations 
and methylations of this particular region have been 
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reported in malignancies such as breast [6, 7], head and 
neck [6, 8], oral squamous cell carcinoma [9], prostate 
[10], colorectal [11–13], liver [14], lung [6] and skin 
[6] cancer. In addition, decreased CSMD1 expression 
has been linked to poor prognosis in patients [9, 15, 16]. 
Thus, CSMD1 was implied to act as a putative tumor 
suppressor gene [5]. However, these studies have 
only showed varying expression of CSMD1 by using 
commercial peptide-specific antibodies or genetic 
screening for deletions that covers regions with several 
genes. Therefore, the assumption that CSMD1 acts as 
tumor suppressor gene remains unsubstantiated with a 
direct experimental approach.
In the present study, by using in vitro and in vivo 
approaches, we aimed to determine whether CSMD1 acts 
as a tumor suppressor protein in breast cancer progression.
RESULTS
CSMD1 expression in human breast cancer 
tissues is decreased and correlates with poor 
prognosis
First, we set out to evaluate the expression of 
CSMD1 in paraffin-embedded normal breast tissue. To 
validate our approach of using an RNAscope assay for 
detection of CSMD1 mRNA, we prepared BT-20 cells 
differing in expression of CSMD1 treated the same way 
as human tissues. Strong mRNA signal (brown dots) was 
observed for the positive control (PPIB, cyclophilin) in 
both BT-20 CSMD1- and control-transfected cells, whereas 
the CSMD1-specific mRNA signal was only detected 
in BT-20 expressing CSMD1. No signal was found for 
the negative control DapB probe (Figure 1A). Further, 
CSMD1-specific mRNA was detected in normal breast 
tissue, particularly in ductal epithelial cells (Figure 1B). 
Next, we measured the expression of CSMD1 
transcript in a cohort of human breast cancer using 
qPCR. Breast cancer tissues (n = 127) had significantly 
lower levels of the CSMD1 transcript than normal tissues 
(n = 32) (p < 0.05) (Figure 1C). Importantly, patients with 
low CSMD1 levels had a significantly shorter survival 
compared with those who had high levels (117.5 ± 6.6 
month vs 149.3 ± 3.7 months, p < 0.008 by log rank 
analysis) (Figure 1D). Accordingly, tumors with higher 
Nottingham Prognostic Index (NPI) [17] had statistically 
significantly lower levels of CSMD1 transcript (133 +/− 
14 for NPI < 3.4; 18.6 +/−17.8 for NPI 3.4-5.4; 6.4 +/− 4.9 
for NPI > 5.4). These NPI values correspond to 85, 70 and 
50% 5-year survival, respectively.
Additionally, analysis of mRNA expression array 
data for 1600 breast cancer patients with the online survival 
analysis tool KM plot (kmplot.com) supported the tumor 
suppressor function of CSMD1 in an independent patient 
cohort using recurrence-free survival as an endpoint [18]. 
In this dataset, three out of four probes for CSMD1 showed 
significant association with recurrence free survival with 
hazard ratios varying between 0.69 and 0.81 (Figure 1E).
CSMD1 expression and knockdown in breast 
cancer cells
The CSMD1 mRNA expression was examined 
in three breast cancer cell lines by RT-PCR. Due to low 
expression levels (Figure 2B), BT-20 and MDA-MB-231 
cells were selected for expression of CSMD1. On the other 
hand, T47D cells expressed appreciable amounts of CSMD1 
and were therefore chosen for knocking down CSMD1 
expression. Successful expression of CSMD1 in clones 
1/2/3 for BT-20 cells (Figure 2Ci) and 1/2/3 for MDA-
MB-231 cells (Figure 2Di) was detected by conventional 
PCR. The expression of CSMD1 was confirmed by flow 
cytometry analysis with a specific antibody (Figure 2Cii and 
2Dii). In order to knock down the expression of CSMD1 
in T47D cells, we used a ribozyme transgene generated 
previously in which a reduction of CSMD1 was confirmed 
on both the RNA and the protein levels [3].
Increased CSMD1 expression contributes to the 
decreased cancer cell migration and invasion 
No significant differences in cell proliferation were 
observed in any cell line with modified CSMD1 expression 
when compared to the controls (Figure 2Ei–2Eiii). The same 
was true after 72 and 96 hours incubation time (not shown). 
On the other hand, both BT-20 (Figure 3A) and MDA-
MB-231 cells expressing CSMD1 (Figure 3B) displayed a 
significant delay in recovering a scratch wound compared to 
the control cells after 24 hrs. Accordingly, increased wound 
recovery was observed in T47D ∆CSMD1 cells (Figure 3C).
The chemotaxis/migration assay measures the ability 
of cancer cells to move towards an extracellular gradient 
of serum. BT-20 cells expressing CSMD1 (Figure 3D) 
and MDA-MB-231 cells expressing CSMD1 (Figure 3E) 
showed a significant reduction in cellular migration when 
compared to the control cells. The results also indicated a 
trend towards an increase in cellular migration for T47D 
∆CSMD1 cells (Figure 3F). 
When the invasion assay was performed in BT-20 
(Figure 4A) and MDA-MB-231 (Figure 4B) cells, expression 
of CSMD1 markedly reduced the invasive potential of these 
cells. However, when the poorly invasive T47D cells were 
monitored, no significant difference was seen between T47D 
∆CSMD1 cells and the controls (Figure 4C).
Taken together, these data indicate that CSMD1 
expression in human breast carcinoma cells attenuates 
their migratory and invasive traits, both of which are 
hallmarks of tumor cell aggressiveness. 
CSMD1 decreases adhesion 
To further explore the effect of altering levels of 
CSMD1 in transfected cells, the ability to adhere to model 
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extracellular matrix, Matrigel was studied. Expression 
of CSMD1 significantly inhibited the adhesion of BT-20 
cells expressing CSMD1 (Figure 4D) and MDA-MB-231 
cells expressing CSMD1 (Figure 4E). The opposite effect 
was seen for T47D ∆CSMD1 cells, where the adhesive 
potential was significantly increased (Figure 4F). 
Decreased levels of CSMD1 enhance 
tumuorigenic potential of cancer cells
When co-culturing cancer-associated fibroblasts 
(CAFs) and T47D ∆CSMD1 cells (Figure 5A), or control 
fibroblasts and T47D ∆CSMD1 cells (Figure 5B), a 
significant increase in the number of cell colonies was 
observed when compared to the T47D CTRL cells. We also 
found a tendency to form more anchorage-independent 
colonies in agar for the CTRL cells in comparison with 
the MDA-MB-231 cells expressing CSMD1 (Figure 5C). 
To support this observation, we next analyzed a breast 
cancer stem cell-associated parameter, the activity of 
ALDH-1 [19, 20]. ALDH-1 negative cells were defined by 
flow cytometry-based analysis using the ALDH inhibitor 
DEAB. CSMD1 expression in MDA-MB-231 resulted in 
a significant relative decrease of ALDH-positive cells by 
Figure 1: Detection of CSMD1 mRNA in normal breast tissue and quantitation of CSMD1 mRNA transcript in breast 
cancer tissues. CSMD1-specific probe, as well as a negative (DapB) and a positive (PPIB) control probes were included when staining 
BT-20 expressing CSMD1 and CTRL paraffin-embedded cell pellets for validation of the method (A). RNAscope detection of CSMD1 
mRNA transcripts in paraffin-embedded normal breast tissue. Samples were hybridised with either CSMD1-specific probe or negative 
control probe. A positive signal for CSMD1 was observed in the normal breast tissues. The black arrows outlined the mRNA brown dots 
(B). Breast tumor tissues had significantly lower levels of CSMD1 mRNA transcript compared with normal tissues; *p < 0.05 by Mann-
Whitney test (C). Patients with low levels of the CSMD1 transcript showed a significantly shorter overall survival (log rank test) (D). 
Kaplan–Meier plots using as using recurrence-free survival as an endpoint for four probes of CSMD1; HR, hazard ratio (E).
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Figure 2: Expression of CSMD1 in breast cancer cell lines. CSMD1 is composed of CUB and CCP domains followed by a single 
transmembrane domain and a small cytoplasmic region (A). Screening of breast cancer cell lines for CSMD1 coding sequence at mRNA 
level using qPCR. The breast cancer cells BT-20 and MDA-MB-231 were selected for expressing CSMD1 and T47D for knocking-down 
(B). Verification of CSMD1 expression in the 1/2/3 clones for BT-20 and 1/2/3 clones for MDA-MB-231 cells by conventional PCR (i) 
and flow cytometry (ii). CSMD1 levels were higher when compared to the WT. The data presented is representative of a single experiment 
performed in duplicates (C–D). The housekeeping gene GAPDH was used as a control of RNA integrity. Cell viability measured after 
24h incubation (E) was not affected when expressing CSMD1 in the breast cancer cells BT-20 and MDA-MB-231 (i-ii) or when silencing 
CSMD1 in the breast cancer cell T47D (iii). Values are means ± SD from 3 independent experiments performed in five replicates. One-way 
ANOVA was used to calculate statistical significance; ns, not significant.
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16% (Figure 5D). Taken together, CSMD1 diminishes the 
clonogenic properties of cancer cells.
CSMD1 decreased intracellular signaling 
potential of cancer cells
To investigate which phosphorylation events that 
are altered by expression of CSMD1, we utilized a 
phospho-kinase antibody array encompassing 43 kinase 
phosphorylation sites. Cells were serum starved for 
30 min and then lysed to examine protein phosphorylation. 
Following quantification of the densities of individual 
dots corresponding to a panel of phosphorylated kinases, 
we observed an overall diminished signaling potential 
in the MDA-MB-231 breast cancer cells expressing 
CSMD1 in comparison with CTRL cells. Kinases, which 
Figure 3: Alteration of CSMD1 expression affects wound healing and migration. A monolayer of cells was wounded and 
photographs were taken at different time points. The wound closure was expressed as percentage of wound closure as compared with the 
zero time point. Percentage wound closure observed in BT-20 (A), MDA-MB-231 (B) and T47D cells (C). WT, CSMD1 or ∆CSMD1 
cells were compared to CTRL cells by two-way ANOVA to calculate statistical significance. Motile cells that passed through the pores 
and adhered to the underside of the cell culture insert membrane following a FBS gradient were photographed and counted for BT-20 (D), 
MDA-MB-231 (E) and T47D cells (F). A one-way ANOVA was used to calculate statistical significance between the CTRL cells and WT, 
CSMD1 or ∆CSMD1 cells; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. Results shown are mean of cells counts ± SD from 3 
independent experiments performed in duplicates.
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were phosphorylated to a lower degree in the presence 
of CSMD1 in statistically significant manner included: 
epidermal growth factor receptor (EGFR), Akt1/2/3, 
glycogen synthase kinase-3 (GSK-3), extracellular 
signal–regulated kinases (ERK1/2), mitogen- and stress-
activated kinases-1 and -2 (MSK 1/2), oncogene p53, 
focal adhesion kinase (FAK), SRC kinases Lyn and 
Yes, as well as STAT2 (Figure 6A–6D). We grouped 
the kinases according to their roles in different major 
signaling pathways that play prominent roles in breast 
cancer progression [21–24]. We found that the EGFR/
PI3K/AKT, p38 MAPK and SRC-FAK pathways were the 
Figure 4: Forced expression of CSMD1 decreases cell invasion and adhesive capacity. (A–C) Cells capable of invading and 
migrating through a layer of matrigel to the underside of the cell culture insert membranes were photographed and counted after crystal 
violet staining for BT-20 (A), MDA-MB-231 (B) and T47D cells (C). Data are shown as the mean of cells counts ± SD from 3 independent 
experiments performed in single inserts. (D–F) Adherent cells to matrigel were photographed and counted after crystal violet staining for 
BT-20 (D), MDA-MB-231 (E) and T47D cells (F). Results shown are mean of cells counts ± SD from 3 independent experiments performed 
in at least four replicate. A one-way ANOVA was used to calculate statistical significance between the CTRL cells and CSMD1 expressing 
cells; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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most affected pathways, whereas the effect on the STAT 
pathway was moderate.
CSMD1 expressing cancer cells exhibited low 
incidence of metastatic in vivo
To examine the role of CSMD1 in vivo, control- or 
CSMD1-transfected MDA-MB-231 cells were injected 
into the mammary fat pad of SCID mice. No significant 
differences in the tumor growth of the primary tumors were 
observed between the two groups of mice (Figure 7A). 
However, in the control group we observed 3–4 fold 
enlarged lymph nodes in 5 of 9 animals suggesting lymph 
node metastases. In contrast, in the CSMD1 expressing 
group none of 9 animals had enlarged lymph nodes 
(Figure 7B). We also observed a dramatic decrease in the 
number of metastases formed in lungs when comparing 
CSMD1 expressing tumors and controls (Figure 7C).
We then evaluated the ability of cancer cells to 
extravasate to the site of metastasis. For this purpose 
fluorescently labeled control- and CSMD1-transfected 
MDA-MB-231 cells were injected intravenously into 
SCID mice and counted in lung tissue sections taken after 
24 h. The data suggest that the expression of CSMD1 does 
not influence the extravasation process, as the number of 
fluorescent cancer cells that entered via circulation to 
the lungs was not significantly different between the two 
groups (Figure 7D). Even though there was a small trend 
towards diminished extravasation of cancer cells to the 
lung in the CSMD1 group, this cannot explain the drastic 
Figure 5: Clonogenicity of ∆CSMD1 cells was stimulated by breast fibroblasts. Co-culture of T47D ∆CSMD1 or CTRL 
cells with either CAFs (A) or control fibroblasts (Fibro-2) (B) was analysed. Colonies were photographed and counted after toluidine blue 
staining. Results shown are mean of colony counts ± SD from 3 independent experiments performed in at least three replicate. Unpaired 
Student’s t-test was used to calculate statistical significance between the observed differences; **p < 0.01. Anchorage-independent growth 
in agar was decreased in CSMD1 expressing cells (C) MDA-MB-231 CTRL and CSMD1 expressing cells were cultured in soft agar for 
3 weeks. Colonies formed were photographed and counted. Results shown are mean of total area of colonies per number of colonies ± SD 
analysed in Image J from 3 independent experiments. CSMD1 expressing cells exhibit a smaller sub-population of cells with enhanced 
ALDH-1 activity (D) Flow cytometry analysis of ALDH-1 activity was performed in MDA-MB-231 WT and CSMD1 expressing cells 
using ALDEFLUOR® assay kit. For all samples in order to determine the ALDH-1 negative cells, fraction of ALDEFLUOR®-stained cells 
was immediately quenched with DEAB, a specific ALDH-1 inhibitor. Left-hand panels show representative histograms of MDA-MB-231 
CTRL (i) and MDA-MB-231 CSMD1 (ii) ALDEFLUOR and DEAB treated samples and the corresponding dot plots in the smaller right 
panels in each case. Right-hand panel (iii) shows mean values for ratio between ALDH-1 and DEAB MFI obtained in three independent 
experiments. Unpaired Student’s t-test was used to calculate statistical significance of the observed difference; *p < 0.05.
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difference in the occurrence of metastatic foci observed in 
the previous experiment. These observations together lead 
to the conclusion that CSMD1 likely influences the rate of 
escape of tumor cells from the primary tumor.
DISCUSSION
CSMD1 is a large transmembrane protein suggested 
to act as tumor suppressor on the basis of genetic findings, 
i.e. mutations and deletions in the CSMD1 gene are 
associated with different types of cancer including breast 
cancer [7, 25]. These deletions are generally associated with 
poor prognosis and a more malignant cancer phenotype. In 
this study, we provide direct experimental evidence that 
CSMD1 acts as a tumor suppressor gene, and we revealed 
some mechanisms responsible for this function.
Consistent with the previously observed presence 
of CSMD1 mRNA in whole breast tissue [3], the current 
in situ hybridisation analysis of CSMD1 mRNA revealed 
the expression of CSMD1 in ductal epithelial cells. The 
tumor suppressor role of CSMD1 was strongly supported 
by our clinical observation that breast cancer tissues had 
low levels of CSMD1 compared with normal mammary 
tissues, and the fact that low levels of the transcript 
were significantly associated with a shorter survival of 
the patients. This was also supported by data from an 
independent cohort (KM plot). A similar observation was 
previously made using immunohistochemistry in which 
low CSMD1 protein levels were linked to high tumor 
grade and shorter overall survival [7]. 
This current report is the first to study the effect 
of CSMD1 expression on the biological properties of 
epithelial breast cancer cells. The panel of breast cancer 
cells used has served as a suitable model to demonstrate 
that CSMD1 acts as a tumor suppressor. First we found 
that changes in the expression of CSMD1 did not 
modify the growth of the cancer cells, which simplified 
interpretation of the following migration and invasion 
assays. Metastasis is a complex process involving a 
number of steps that must be accomplished for the cancer 
cell to effectively penetrate the basement membranes. 
The atypical motile behavior that cancer cells display is 
a common feature among all types of solid tumors. We 
therefore performed wound healing assays to study the 
random movement of cancer cells on a solid surface. 
The closure of the wound occurred notably faster in cells 
Figure 6: Analysis of phosphorylation of main kinases. CTRL and CSMD1 expressing MDA-MB-231 cells were lysed and 
phosphorylation of panel of kinases was evaluated using Proteome Profiler Array (Phospho-kinase Array Kit). Quantification of mean spot 
pixel densities obtained for CTRL and CSMD1 cells was depicted in the plots categorized in different pathways (A) EGFR PI3K AKT (B) 
p38 MAPK (C) STAT (D) SRC-FAK pathway. A one-way ANOVA was used to calculate statistical significance between the CTRL cells 
and CSMD1 cells; *p < 0.05; **p < 0.01; ***p < 0.001.
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lacking CSMD1 than in the expressing cells. A similar 
effect was observed when investigating directional 
migration in response to a serum gradient, indicating 
that CSMD1 inhibits epithelial cell motility. Since cell 
migration requires an active interaction between the cells 
and the substrate on which they are attached, we next 
examined adhesion of the cells with altered levels of 
CSMD1. Unexpectedly, expression of CSMD1 decreased 
cellular adhesion to an artificial basement membrane. 
The opposite was observed when silencing CSMD1. 
Apparently, the observed effect on attachment was 
minor compared to the opposite effect on cell migration 
and therefore not observed in the latter assays. The 
decreased adhesion in the presence of CSMD1 could be 
beneficial in the later step of metastasis when cancer cells 
attach to the target tissue. Invasion refers to the ability 
of the cancer cells to penetrate the surrounding tissues 
through the degradation of the basement membrane and 
the extracellular matrix. CSMD1 reduced the invasive 
potential of CSMD1 expressing cells, particularly in 
the highly invasive MDA-MB-21 cells. For the weakly 
invasive BT-20 cells, the effect was less pronounced. 
Considering that T47D cells are a non-invasive cell line, 
the lack of effect upon deletion of CSMD1 was expected. 
Figure 7: CSMD1 expressing MDA-MB-231 cells do not form metastatic foci in xenograft model. (A) The CTRL and 
CSMD1-transfected cells were injected into the mammary fat pad of SCID (CB-17/Icr-Prkdcscid/Rj) mice and tumor volumes were measured 
for 60 days or until the tumors reached 1 cm3. The data represents mean tumor volumes ±SD of the 10 animals in each group (B, C) The 
lymph nodes and lungs were extracted and stained for hematoxylin and eosin (B) Representative hematoxylin and eosin staining of lymph 
nodes indicating the difference in size between the two groups. (C) Representative sections of lung tissue with black arrows indicate the 
metastatic lesions. Results shown are means of metastatic lesions bigger than 50 µm counted on each slide ± SD (n = 5 per group). Unpaired 
Student’s t-test was used to calculate statistical significance of the observed difference; *p < 0.05 (D) Immunostaining of lung tissue for 
CD31 (red) and extravasated tumor cells (green) after intravenous injection of fluorescent labelled CTRL and CSMD1 expressing MDA-
MB-231 cells. Results shown are means of number of metastatic cells counted on each slide ± SD (n = 8 per group).
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Over the last decade, it has become apparent that 
the tumor microenvironment is a key modulator of tumor 
progression and metastasis. CAFs are the most abundant 
cell type in the tumor stroma [26]. They are associated 
with numerous steps of the metastatic cascade, both in the 
primary site and in the secondary tumor in a distant organ 
[27, 28]. Thus, we studied the effect of CAFs and control 
fibroblasts on tumor cells with modified levels of CSMD1 
on the survival and proliferation using direct physical 
contact between cancer cells and fibroblasts. BT-20 
and MDA-MB-231 cells did not form visible colonies 
but rather grew in layers on top of fibroblasts. In contrast, 
T47D cells lacking CSMD1 were significantly affected 
by the presence of both types of fibroblasts and showed 
enhanced cell growth and clonogenicity compared to 
control T47D cells expressing CSMD1. 
It is now commonly accepted that a subset of cells 
within a tumor possess unique tumorigenic properties 
similar to stem cells, also responsible for the metastasis in 
a secondary site [29]. Interestingly, the ability of cells to 
initiate spheroid-colony growth in soft agar was inhibited 
in CSMD1 expressing cells, suggesting altered stem-like 
characteristics of cancer cells. Furthermore, CSMD1 
expression resulted in decreased ALDH-1 activity, a key 
enzyme involved in stem cell differentiation [19], likely 
translating to lower tumorigenic capacity. 
CSMD1 has a small cytoplasmic tail of 56 amino 
acids with a putative tyrosine phosphorylation site. 
Therefore, CSMD1 may serve as a receptor or a co-receptor 
for unknown ligands and may be involved in signal 
transduction. Our data offers support for the involvement 
of CSMD1 in different signaling pathways with an overall 
decrease of the cell signaling potential, correlating with the 
observed functional properties of cancer cells expressing 
CSMD1.
Observations from the patient tissues and the 
in vitro data obtained with three different cell lines were 
confirmed by in vivo experiments with CSMD1 expressing 
breast cancer cells. Here, we found no measurable effect 
of CSMD1 expression on the growth of primary tumors 
but we detected a striking difference in the ability of 
the cancer cells to metastasize to secondary sites. Thus, 
MDA-MB-231 cells expressing CSMD1 essentially lost 
the ability to metastasise, while control cells formed 
readily metastases in lymph nodes and lungs. We did not 
observe differences in lymphocyte infiltration in tumors 
sections (staining for CD45; data not shown), indicating 
that the tumor-suppressing activities of CSMD1 are not 
linked to its complement inhibitory function. Furthermore, 
experiments showing no difference in extravasation of 
CSMD1 expressing cells into lungs compared to control 
cells, indicated that the difference lies in the ability of the 
cells to detach from the primary tumor. This is consistent 
with our observations that CSMD1 expressing cells are 
less motile and invasive, displaying less stem cell-like 
properties.
In summary, we provide experimental evidence for 
the role of CSMD1 as a tumor suppressor in vitro and 
in vivo in the progression of breast cancer. We revealed 
that expression of CSMD1 significantly reduced cell 
motility and migration, adhesion and invasion, as well as 
the tumorigenic and signaling potential of human breast 
cancer cells. Conversely, knockdown of CSMD1 enhanced 
cell motility and cell adhesion as well as clonogenic 
potential. Furthermore, expression of CSMD1 in vivo 
resulted in diminished formation of metastatic foci in a 
xenograft model likely due to impaired rate of escape 
of tumor cells from the primary tumor. Collectively, 
our results confirm that low levels of CSMD1 in breast 
cancer cells are associated with more aggressive cancer 
cell behavior, hence demonstrating the role of CSMD1 as 
tumor suppressor gene.
MATERIALS AND METHODS
Cell lines, culture conditions and mammary 
tissues
The human breast cancer cell lines BT-20, MDA-
MB-231 and T47D were purchased directly from ATCC 
and all the experiments were performed on cultures 
within no more than 5 passages. Stable transfectants 
were cultured with addition of 3 µg/ml puromycin 
(BT-20 and MDA-MB-231; Invitrogen) or 5 μg/ml of 
blasticidin S (T47D; Invitrogen). Generation of human 
breast carcinoma-associated fibroblasts (CAFs) and the 
corresponding control fibroblasts was described [30]. 
All cells were maintained in DMEM (Thermo Scientific) 
supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin. All cells were monthly tested for 
Mycoplasma contamination with VenorGEM Classic kit 
(Minerva Biolabs). 
Fresh frozen mammary tissues (normal, n = 32 and 
tumor, n = 127) from patients with breast cancer were 
collected immediately after surgery, under the research 
ethics approval from the Southeast Wales Research Ethics 
Committee, and stored at −80°C until used. Patients were 
followed up routinely in the clinics with a median follow-
up at 120 months and their clinical characterisation was 
published previously [31].
In situ hybridisation staining
In situ hybridization was used for detection of 
CSMD1 mRNA in paraffin-embedded normal breast 
tissue sections and pellets of BT-20 CSMD1 or control-
transfected cells. Tumor material was obtained from 
female patients diagnosed with invasive breast cancer 
at Malmö University Hospital [32]. Ethical permission 
was obtained from the Lund University Regional Ethics 
Board, ref. no. 445/2007 whereby written consent was 
not required and patients were offered the possibility to 
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opt out. After baking the slides at 60°C for 1 hour and 
deparaffinisation in xylene followed by dehydration in 
absolute ethanol, CSMD1-specific RNA, peptidylprolyl 
isomerase B, PPIB (cyclophilin) housekeeping gene RNA 
(positive control) and dihydrodipicolinate reductase from 
Bacillus subtilis, DapB RNA (negative control) were 
detected using RNAscope 2.0 BROWN assay (Advanced 
Cell Diagnostics) [33]. Pictures were taken using an 
Aperio ScanScope (Leica Microsystems). The images 
were processed in Adobe Photoshop in order to distinguish 
condensed nucleoli (grey/violet) from the signal from the 
RNA probes (brown) [34].
Modification of CSMD1 expression in breast 
cancer cells 
For over-expression, a p509 plasmid containing 
CSMD1 cDNA (DNA 2.0) was transfected into the cells, 
in parallel with an empty p509-GFP plasmid. The protein 
sequence was exactly as in GenBank: AAQ88541.1, but the 
DNA sequence was optimized for high expression. Cells 
were transfected using Lipofectamine 2000 (Invitrogen) or 
FuGENE HD (Promega) and clones picked after selection 
in antibiotics. The cells expressing CSMD1 were designated 
as CSMD1, those containing the control p509-GFP plasmid 
were designated as CTRL, unaltered wild type cells were 
designated as WT. T47D cell line demonstrating reduced 
CSMD1 levels was generated previously using a ribozyme 
transgene system [3] and designated as ∆CSMD1.
RNA extraction, PCR and real time qPCR
RNA was isolated from picked colonies using 
Trizol (Invitrogen). The quality of the RNA was assessed 
using an Experion RNA StdSens Analysis Kit (Bio-Rad). 
RNA was converted to cDNA using 2.5 µM Oligo(dT) 
primer, 24 U RnaseOUT riblonuclease inhibitor, 200 U 
Superscript III reverse transcriptase (Invitrogen) and 0.5 
mM dNTPs (Fermentas). 
Conventional PCR was performed in a 
S1000 Thermal-Cycler (Bio-Rad) using REDTaq® 
ReadyMixTM PCR Reaction mix (Sigma-Aldrich). 
Primer sequences for CSMD1 were: forward primer 5′- 
AGATGCTGCCGTCAAAAGATGGAT-3′ and reverse 
5′- TCACTTTGTCTGGGTCCGTTGTTG-3′. GAPDH 
was used as internal loading control. To quantify transcript 
copy number of CSMD1, Taqman assays (Applied 
Biosystems) were used. Samples were tested in triplicate 
and CSMD1 (Hs00899098_m1) gene expression level 
was calculated using the ΔCT method after normalisation 
with the geometric mean of the three housekeeping 
genes; cyclophilin A (Hs99999904_m1), TATA box 
binding protein (Hs0042761_m1) and hypoxanthine 
phosphoribosyltransferase 1 (Hs99999909_m1). 
For mammary samples, tissues were homogenised 
and total RNA was extracted, quantified and subjected to 
a reverse transcription kit (PrimerDesign). Quantification 
of the CSMD1 and the house keeping actin transcripts 
were carried using the Ampliflor technology in which a 
uniprimer with a Z-sequence (underlined in the following) 
was used as a probe. The primer sequence for CSMD1 
and actin were respectively (5′ - 3′): aggagatgagaggccaag 
vs actgaacctgaccgtacaccccataaactgtcaacg, and ctgagtacgt 
cgtggagtc vs actgaacctgaccgtacacagagatgaccctttg
Analysis of cell surface CSMD1 by flow 
cytometry 
Cells were detached with versene and incubated 
with rabbit anti-CSMD1 antibody generated against 
recombinantly expressed CCP2/CUB3 domains (Agrisera). 
The cells were then washed twice and incubated with 
FITC-labelled swine anti-rabbit IgG diluted (Dako) for 30 
min at room temperature, and analysed by flow cytometry 
(Partec Cyflow) and FlowJo software.
Cell viability assay
Cells were seeded in a 96-well plate and grown 
under standard conditions for 24 hours and 100 µl of fresh 
medium with 10% of alamarBlue (Invitrogen) was added 
to the cells for 6 hours. Absorbance was determined at a 
wavelength of 570/600 nm using a microtiter plate reading 
spectrophotometer (Cary 50 Bio). 
Wound healing assay
Cells were grown to confluency in a 6-well plate 
and the monolayer was scratched with a sterile pipette tip 
to create a wound. Cells were photographed immediately 
after wounding and every 2/4/6/24 hours with EVOS FL 
inverted microscope at ×10 magnification. Image J was 
used to determine the wound area and percentage wound 
closure was calculated.
Chemotaxis/migration assay
The motility of cancer cells was studied using cell 
culture inserts (8 µm or 3 µm pore size) placed into a 24-
well plate (Corning). Cells were seeded in the inserts with 
1–10% FBS chemotactic gradient. After incubation period, 
the cells that had migrated through the porous membrane 
were fixed in 4% formaldehyde for 10 minutes before 
being stained in 0.5% crystal violet (Merck Millipore). 
The cells were then photographed at ×40 magnification. 
Three random fields were counted for each duplicate 
insert.
Matrigel adhesion assay
The cell-matrix attachment was carried out as 
previously described [35]. Briefly, cells were added to 
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96-well plate coated with Matrigel (BD Bioscience) 
and incubated at 37oC for 40 minutes. The membrane 
was washed 5 times, then fixed in 4% formaldehyde for 
10 minutes before being stained in 0.5% crystal violet. 
The number of adherent cells was counted from 2 random 
fields per well and minimum of 4 replicate wells per 
sample at ×40 magnification. 
Invasion assay
Invasiveness was determined using 24-well plate 
BioCoat Matrigel chambers (Corning). Cells were seeded 
in the inserts with 1–10% FBS chemotactic gradient. The 
plates were then incubated for 24/48/72 hours at 37°C and 
the matrigel layer together with the non-invasive cells was 
removed with a cotton swab. The cells that have migrated 
through the Matrigel and porous membrane of the insert 
were fixed in 4% formaldehyde for 10 minutes before 
being stained in 0.5% crystal violet. The cells were then 
visualised at ×40 magnification. Three random fields were 
counted for each test sample.
Clonogenic assay
CAFs and control fibroblasts were seeded in a 
96-well plate (5000 cells per well) in order to create a 
confluent monolayer of fibroblast. Then, 50 cells were 
seeded on top of the fibroblasts. After 10 days the cells 
were fixed with 70% ethanol for 10 minutes before 
being stained in 0.1% toluidine blue. The colonies were 
photographed at ×4 magnification. A colony was defined 
as a cluster of minimum 50 cancer cells. 
Soft agar colony formation 
A 0.6% (w/v) bottom layer of low melting point 
agarose in normal medium was prepared in Petri dishes 
(90 mm). On top, a layer of 0.3% agarose containing 
30 000 cells was placed. The cells were fed twice a week 
with normal medium. After 4 weeks, colonies were stained 
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide, photographed using CCD camera and counted 
with Image J. 
Identification of aldehyde dehydrogenase 
(ALDH-1) positive cells
The Aldefluor assay was carried out according 
to guidelines (StemCell Technologies). Briefly, 1*106 
cells were stained with Aldefluor reagent (1 µM) in 
assay buffer. As a parallel negative control the reaction 
was stopped with 50 mM of the specific ALDH-1 
inhibitor diethylaminobenzaldehyde (DEAB). Cells were 
incubated for 1 hour at 37°C, pelleted at 400 g for 5 min, 
resuspended in 1 ml assay buffer and stored on ice prior to 
analysis using flow cytometry. 
Proteome profiler assay
Activity of signaling pathways was investigated 
using the Proteome Profiler arrays (Phospho-kinase Array 
Kit; R&D Systems). These are nitrocellulose membranes 
with antibodies against 43 kinase phosphorylation sites 
and two control antibodies spotted in duplicates. Cell 
lysates from 30 min serum starved CTRL and CSMD1 
expressing cells were prepared in the provided lysis 
buffer. In total, 300 μg of protein was used for each array 
and incubated with the membranes overnight at 4°C. 
The detection was conducted according to manufactures’ 
instructions. Densities of individual dots corresponding 
to a phosphorylated kinase were measured by Image J 
software to compare CTRL and CSMD1 expressing cells.
Animal experiments
Orthotopically injection into the mammary fat pad
MDA-MB-231 CTRL or CSMD1 cells were 
orthotopically transplanted (5 × 106 cells/animal) into the 
4th right inguinal mammary fat pad of 8 weeks old SCID 
(CB-17/Icr-Prkdcscid/Rj) mice. Each group consisted of 10 
animals. Tumor growth was followed twice per week by 
measuring each tumor in two dimensions using a caliper. 
The tumor volume was calculated using the formula 
V = dim1*dim22*π/6; dim1 > dim2. Mice were sacrificed 
when tumors reached the size of 1 cm3. Mice were injected 
with an overdose of tribromoethanol (Sigma) and perfused 
with PBS. Tumors, lungs and lymph nodes were saved for 
further analyses.
Intravenous injection of cancer cells
To analyze tumor cell extravasation 5 × 105 
fluorescently labeled (CellTracker™ Green CMFDA, 
Molecular Probes) MDA-MB-231 CTRL and CSMD1 
cells were injected in the tail vein and allowed to 
circulate for 24 hours. Mice were perfused and sacrificed. 
Cryopreserved lungs were sectioned and analyzed for 
extravasated labeled cells (20× magnification).
Histology and staining
Mice were heart perfused with PBS. Organs 
were fixed in 4% paraformaldehyde, dehydrated and 
paraffinized prior to use by subsequent incubation in 
xylene, ethanol and water. For cryopreservation organs 
were kept in 30% sucrose at 4°C over night, followed 
by embedding in OCT cryomount (Histolab). Tissues for 
RNA extraction were snap-frozen in liquid nitrogen. For 
metastases evaluation we used paraffin embedded right 
lungs of 5 mice per group. The metastatic burden was 
assessed by serial sectioning of the entire lung following 
hematoxylin and eosin (Histolab) staining on every 30th 
section. Metastatic lesions larger than 50 µm were counted 
on each slide. Sections for immunostaining were fixed 
in ice-cold aceton followed by washing with PBS. After 
blocking with serum free protein block (DAKO) 90 min 
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at RT, antibody against CD31 (Clone Mec 13.3, dilution 
1:200, BD pharmingen) was applied in PBS supplemented 
with 1 % BSA at 4°C over night. After washing Alexa flour 
594 donkey anti-rat IgG (Life Technologies, 1:1000) was 
applied for 2 hours at RT. Slides were mounted in DAPI 
containing mounting medium. Imaging was done using an 
Olympus BX63 microscope with Olympus DP80 camera. 
RNA extraction
Snap frozen material was disrupted using 
TissueLyser LT (Qiagen), 5 mm stainless steel beads 
(Qiagen) and reagent DX (Qiagen). The lysate was further 
homogenized using QIAshredder (Qiagen) and RNA was 
extracted using RNeasy mini kit (Qiagen) with on column 
DNAse digest (Qiagen) and additional washing steps. The 
quality of the RNA was assessed using an Experion RNA 
StdSens Analysis Kit (Bio-Rad).
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5.0 and SPSS with methods listed in Figure legends.
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